Strongbridge Biopharma plc Stock News

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to

NEW YORK, May 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc ("Strongb

CHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 /PRNewswire/ -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develo

Penny stocks are in focus as we enter the last week of May. Which companies are you watching?

The stock price of Strongbridge Biopharma plc (NASDAQ: SBBP) increased by over 14% pre-market. This is why it happened.

Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q1 2021 Results - Earnings Call Transcript

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of -10.00% and 2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Strongbridge Biopharma (NASDAQ:SBBP) fell 3.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 42.11% over the past year to ($0.11), wh

~ Reports KEVEYIS ®  (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~

On Wednesday, May 12, Strongbridge Biopharma (NASDAQ:SBBP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

SBBP has an approved product and a late-stage pipeline. However, Cushing's syndrome is a highly-differentiated market.

RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing's Syndrome and Comorbid Diabetes Mellitus

The stock price of Strongbridge Biopharma plc (NASDAQ: SBBP) increased by over 25% during pre-market trading. This is why it happened.

~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~